Artykuły w czasopismach na temat „Anti-IL-23”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Anti-IL-23”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Schwartz, David. "Anti-IL-12/23." Inflammatory Bowel Diseases 15, no. 12 (2009): 1927–28. http://dx.doi.org/10.1002/ibd.20990.
Pełny tekst źródłaGras, J. "Guselkumab. Anti-IL-23 antibody, Antipsoriatic." Drugs of the Future 42, no. 2 (2017): 81. http://dx.doi.org/10.1358/dof.2017.042.02.2564098.
Pełny tekst źródłaHeld, Katherine, William Glass, Yevgeniya Orlovsky, et al. "Generation of a protective T cell response following viral infection of the CNS is independent of either IL-12 or IL-23 (B141)." Journal of Immunology 178, no. 1_Supplement (2007): LB29. http://dx.doi.org/10.4049/jimmunol.178.supp.b141.
Pełny tekst źródłaBrod, Staley A. "Ingested (oral) anti-IL-12/23 inhibits EAE." Journal of the Neurological Sciences 361 (February 2016): 19–25. http://dx.doi.org/10.1016/j.jns.2015.12.011.
Pełny tekst źródłaWendling, Daniel, Clément Prati, Mickael Chouk, and Frank Verhoeven. "Effects of anti-IL-23 and anti-IL-17: The hidden side of spondyloarthritis polymorphism?" Joint Bone Spine 87, no. 1 (2020): 5–7. http://dx.doi.org/10.1016/j.jbspin.2019.06.012.
Pełny tekst źródłaCao, Hao, Qin Lan, Qian Shi, et al. "Anti-IL-23 antibody blockade of IL-23/IL-17 pathway attenuates airway obliteration in rat orthotopic tracheal transplantation." International Immunopharmacology 11, no. 5 (2011): 569–75. http://dx.doi.org/10.1016/j.intimp.2010.11.007.
Pełny tekst źródłaHamada, Kaoru, Yu Sawada, Ryosuke Hino, and Motonobu Nakamura. "HTLV-1 carrier psoriasis patients treated by anti-IL-23/IL-17." Australasian Journal of Dermatology 59, no. 2 (2017): e154-e154. http://dx.doi.org/10.1111/ajd.12701.
Pełny tekst źródłaKyttaris, Vasileios C., Ourania Kampagianni, and George C. Tsokos. "Treatment with Anti-Interleukin 23 Antibody Ameliorates Disease in Lupus-Prone Mice." BioMed Research International 2013 (2013): 1–5. http://dx.doi.org/10.1155/2013/861028.
Pełny tekst źródłaAlhasani, Salam, and Nasser Yousif. "Critical role of IL-23 signaling in prostatic cancer." American Journal of BioMedicine 1, no. 1 (2013): 4–6. http://dx.doi.org/10.18081/ajbm/2333-5106-013-11/4-6.
Pełny tekst źródłaWhitley, Sarah K., Mushi Li, Tracy Tabib, et al. "IL-23 maintains tissue resident memory Th17 cells in murine and psoriatic skin." Journal of Immunology 206, no. 1_Supplement (2021): 98.50. http://dx.doi.org/10.4049/jimmunol.206.supp.98.50.
Pełny tekst źródłaHao, Jing-Sheng, and Bao-En Shan. "Immune enhancement and anti-tumour activity of IL-23." Cancer Immunology, Immunotherapy 55, no. 11 (2006): 1426–31. http://dx.doi.org/10.1007/s00262-006-0171-5.
Pełny tekst źródłaRanzinger, D., J. Thomas, A. C. Pilz, P. Seiringer, S. Eyerich, and K. Eyerich. "045 Anti-IL-23 preferentially inhibits pathogenic TH17 cells." Journal of Investigative Dermatology 143, no. 5 (2023): S8. http://dx.doi.org/10.1016/j.jid.2023.03.046.
Pełny tekst źródłaBlauvelt, Andrew, Mark G. Lebwohl, and Robert Bissonnette. "IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies." Journal of Investigative Dermatology 135, no. 8 (2015): 1946–53. http://dx.doi.org/10.1038/jid.2015.144.
Pełny tekst źródłaLeong, Xue Bin, Chuan Zhe Tang, Chloe Zi Ying Lee, Zoe Ling Hui Lee, and Thai Hau Koo. "Comparative Role of Anti-TNF Agents versus IL-12/23 Inhibitors in Inflammatory Bowel Disease: An Updated Review." Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy 25, no. 3 (2024): 57–61. https://doi.org/10.24871/253202457-61.
Pełny tekst źródłaMiyagawa, Hanae, Hiromichi Hara, Jun Araya, et al. "Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis." PLOS ONE 16, no. 1 (2021): e0245284. http://dx.doi.org/10.1371/journal.pone.0245284.
Pełny tekst źródłaYago, Toru, Yuki Nanke, Manabu Kawamoto, et al. "IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats." Arthritis Research & Therapy 9, no. 5 (2007): R96. http://dx.doi.org/10.1186/ar2297.
Pełny tekst źródłaLee, Hyun Seung, Da-Eun Park, Ji-Won Lee, et al. "IL-23 secreted by bronchial epithelial cells contributes to allergic sensitization in asthma model: role of IL-23 secreted by bronchial epithelial cells." American Journal of Physiology-Lung Cellular and Molecular Physiology 312, no. 1 (2017): L13—L21. http://dx.doi.org/10.1152/ajplung.00114.2016.
Pełny tekst źródłaMatteo, Auriemma, Caponio Chiara, Ruggiero Carlo, Giuliani Federica, and Amerio Paolo. "Anti-IL-12/IL-23 treatment for a psoriatic patient with heart failure." International Journal of Case Reports and Images 4, no. 5 (2013): 266. http://dx.doi.org/10.5348/ijcri-2013-05-309-cr-6.
Pełny tekst źródłaCosta, Luisa, Roberta Ramonda, Augusta Ortolan, et al. "Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment." Clinical Rheumatology 38, no. 9 (2019): 2355–62. http://dx.doi.org/10.1007/s10067-019-04663-6.
Pełny tekst źródłaFrieder, Jillian, Dario Kivelevitch, Isabel Haugh, Ian Watson, and Alan Menter. "Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions." Clinical Pharmacology & Therapeutics 103, no. 1 (2017): 88–101. http://dx.doi.org/10.1002/cpt.893.
Pełny tekst źródłaWan, Y., M. Zhu, J. Gai, Y. Huang, and Y. Hu. "P0640 Development and characterization of LQ080, a novel extended half-life bispecific TL1A/IL-23 p19 single domain antibody for the treatment of IBD." Journal of Crohn's and Colitis 19, Supplement_1 (2025): i1259. https://doi.org/10.1093/ecco-jcc/jjae190.0814.
Pełny tekst źródłaHo, Ji-Chen, Chih-Hung Lee, and Shang-Hung Lin. "No Significant Reduction of Circulating Endothelial-Derived and Platelet-Derived Microparticles in Patients with Psoriasis Successfully Treated with Anti-IL12/23." BioMed Research International 2016 (2016): 1–6. http://dx.doi.org/10.1155/2016/3242143.
Pełny tekst źródłaLi, Yuanteng Jeff, Pavlos Msaouel, Matthew Campbell, Patrick Hwu, Adi Diab, and Sang T. Kim. "Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series." RMD Open 10, no. 3 (2024): e004308. http://dx.doi.org/10.1136/rmdopen-2024-004308.
Pełny tekst źródłaLiu, Haiyan, Yonghao Liu, Yuan Song, and Bo Hu. "IL-23 promotes the development of hepatocellular carcinoma through the induction of IL-17-producing ILC3 (TUM10P.1044)." Journal of Immunology 194, no. 1_Supplement (2015): 211.25. http://dx.doi.org/10.4049/jimmunol.194.supp.211.25.
Pełny tekst źródłaCao, S., K. Ma, and P. Deepak. "DOP095 IL-23-activated cells as response biomarkers for risankizumab in Crohn’s disease patients." Journal of Crohn's and Colitis 19, Supplement_1 (2025): i254—i256. https://doi.org/10.1093/ecco-jcc/jjae190.0134.
Pełny tekst źródłaMisra, Durga Prasanna, Smriti Chaurasia, and Ramnath Misra. "Increased Circulating Th17 Cells, Serum IL-17A, and IL-23 in Takayasu Arteritis." Autoimmune Diseases 2016 (2016): 1–8. http://dx.doi.org/10.1155/2016/7841718.
Pełny tekst źródłaZhang, Yingli, Rongrong Liang, Aicen Xie, Wenqian Shi, Huarong Huang, and Yingqiang Zhong. "Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway." Mediators of Inflammation 2020 (April 28, 2020): 1–13. http://dx.doi.org/10.1155/2020/1719467.
Pełny tekst źródłaSchmitt, Heike, Ulrike Billmeier, Walburga Dieterich, et al. "Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease." Gut 68, no. 5 (2018): 814–28. http://dx.doi.org/10.1136/gutjnl-2017-315671.
Pełny tekst źródłaLi, Hao, Hui-Chen Hsu, Jun Li, et al. "IL-23 induces IRF5 and polarizes inflammatory M1 macrophages to promote inflammation in a mouse model of arthritis (171.5)." Journal of Immunology 188, no. 1_Supplement (2012): 171.5. http://dx.doi.org/10.4049/jimmunol.188.supp.171.5.
Pełny tekst źródłaGargiulo, Luigi, Luciano Ibba, Alessandra Narcisi, et al. "Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study." Dermatology Practical & Conceptual 14, no. 4 (2024): e2024250. http://dx.doi.org/10.5826/dpc.1404a250.
Pełny tekst źródłaFeng, Ting, Hongwei Qin, Lanfang Wang, Etty Benveniste, Charles Elson, and Yingzi Cong. "Microbiota antigen specific Th17 cells induce colitis and promote Th1 cell response through IL-17 induction of innate cell IL-12 and IL-23 production (47.3)." Journal of Immunology 184, no. 1_Supplement (2010): 47.3. http://dx.doi.org/10.4049/jimmunol.184.supp.47.3.
Pełny tekst źródłaKlune, John R., Christian Bartels, Jing Luo, Shinichiro Yokota, Qiang Du та David A. Geller. "IL-23 mediates murine liver transplantation ischemia-reperfusion injury via IFN-γ/IRF-1 pathway". American Journal of Physiology-Gastrointestinal and Liver Physiology 315, № 6 (2018): G991—G1002. http://dx.doi.org/10.1152/ajpgi.00231.2018.
Pełny tekst źródłaJosé, Anthar Ávalos Narváez, Daniel Solís Dittrich Kevin, Elisa González Robles María, Jiménez Zaragoza Michelle, Arturo Ovilla Alvarez Ricardo, and Aréchiga López Mayra. "Advances in Monoclonal Antibody Therapy for Moderate to Severe Psoriasis: Targeting TNF, IL-17, And IL-23 Pathways for Optimal Disease Management." International Journal of Medical Science and Clinical Research Studies 5, no. 05 (2025): 766–69. https://doi.org/10.5281/zenodo.15502235.
Pełny tekst źródłaFried, Richard, Mark Lebwohl, Miriam Bettencourt, John Koo, and Abby Jacobson. "Onset of Plaque Psoriasis Treatment Responses With Anti-IL-17/IL-23 Biologic Therapies." Journal of Drugs in Dermatology 21, no. 8 (2022): 854–60. http://dx.doi.org/10.36849/jdd.66791.
Pełny tekst źródłaCao, S., M. Colonna, and P. Deepak. "DOP19 High dimensional profiling of IL-23-responsive cells revealed molecular signatures that predict response to anti-IL-23 therapy in patients with Crohn’s Disease." Journal of Crohn's and Colitis 18, Supplement_1 (2024): i106—i107. http://dx.doi.org/10.1093/ecco-jcc/jjad212.0059.
Pełny tekst źródłaLiu, Yonghao, Yuan Song, Lei Lei, Yuhui Huang, and Haiyan Liu. "NCR−ILC3 as the initial responders to liver inflammatory environment promote HCC development through IL-23/IL-17 axis." Journal of Immunology 200, no. 1_Supplement (2018): 122.1. http://dx.doi.org/10.4049/jimmunol.200.supp.122.1.
Pełny tekst źródłaFischer, Katarzyna, Hanna Przepiera-Będzak, Marcin Sawicki, Anna Walecka, Iwona Brzosko, and Marek Brzosko. "Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease." Mediators of Inflammation 2017 (2017): 1–9. http://dx.doi.org/10.1155/2017/9401432.
Pełny tekst źródłaQuiniou, Christiane, Maria Domínguez-Punaro, Frank Cloutier, et al. "Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 307, no. 10 (2014): R1216—R1230. http://dx.doi.org/10.1152/ajpregu.00540.2013.
Pełny tekst źródłaCao, Siyan, Kaiming Ma, and Parakkal Deepak. "IL-23-ACTIVATED CELLS PREDICT RESPONSE TO RISANKIZUMAB IN CROHN’S DISEASE." Inflammatory Bowel Diseases 31, Supplement_1 (2025): S56—S57. https://doi.org/10.1093/ibd/izae282.135.
Pełny tekst źródłaRudner, Xiaowen L., Kyle I. Happel, Erana A. Young, and Judd E. Shellito. "Interleukin-23 (IL-23)-IL-17 Cytokine Axis in Murine Pneumocystis carinii Infection." Infection and Immunity 75, no. 6 (2007): 3055–61. http://dx.doi.org/10.1128/iai.01329-06.
Pełny tekst źródłaLyssia, B., M. Caroline, M. Aurore, et al. "DOP031 Anti-IL-7 receptor plus anti-IL12/23 combination induces complete histological normalization in chronic colitis." Journal of Crohn's and Colitis 19, Supplement_1 (2025): i139. https://doi.org/10.1093/ecco-jcc/jjae190.0070.
Pełny tekst źródłaKroenke, Mark A., Thaddeus J. Carlson, Anuska V. Andjelkovic, and Benjamin M. Segal. "IL-12– and IL-23–modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition." Journal of Experimental Medicine 205, no. 7 (2008): 1535–41. http://dx.doi.org/10.1084/jem.20080159.
Pełny tekst źródłaChu, Yi-Lun, and Sebastian Yu. "Hidradenitis Suppurativa: An Understanding of Genetic Factors and Treatment." Biomedicines 12, no. 2 (2024): 338. http://dx.doi.org/10.3390/biomedicines12020338.
Pełny tekst źródłaAli Shareef, Saja, Risala H. Allami, and Ruqaya M. Al-ezzy. "Correlation between Interleukin-23, Autoantibodies and Thyroid Profile in a Sample of Iraqi Patients with Hashimoto’s Thyroiditis." IOP Conference Series: Earth and Environmental Science 1325, no. 1 (2024): 012024. http://dx.doi.org/10.1088/1755-1315/1325/1/012024.
Pełny tekst źródłaHu, Xiaorong, Ruisong Ma, Jiajia Lu, et al. "IL-23 Promotes Myocardial I/R Injury by Increasing the Inflammatory Responses and Oxidative Stress Reactions." Cellular Physiology and Biochemistry 38, no. 6 (2016): 2163–72. http://dx.doi.org/10.1159/000445572.
Pełny tekst źródłaHong, Huixian, Qi Wu, PingAr Yang, et al. "A novel mechanism for IL-23 to up-regulate AICDA and promote pathogenic autoantibodies in lupus." Journal of Immunology 200, no. 1_Supplement (2018): 40.1. http://dx.doi.org/10.4049/jimmunol.200.supp.40.1.
Pełny tekst źródłaYoshida, Hiroki, Yoshiyuki Miyazaki, Sen Wang, and Shinjiro Hamano. "Regulation of Defense Responses against Protozoan Infection by Interleukin-27 and Related Cytokines." Journal of Biomedicine and Biotechnology 2007 (2007): 1–7. http://dx.doi.org/10.1155/2007/79401.
Pełny tekst źródłaPang, Dan-Dan, Li Cai, Jing-Ru Zhang, and Sheng-Ming Dai. "IL-23 induces the expression of pro-osteogenic factors in osteoclasts." Aktuelle Rheumatologie 45, no. 05 (2020): 467–74. http://dx.doi.org/10.1055/a-1099-9028.
Pełny tekst źródłaCairns, J., S. Monkley, S. Tian, et al. "DOP06 Deep characterization of IL-23 pathway in different gut segments and associated plasma biomarkers in inflammatory bowel disease." Journal of Crohn's and Colitis 17, Supplement_1 (2023): i64—i67. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0046.
Pełny tekst źródłaLee, Priscilla, Alan Smith, Yuhong Yang, Michael Racke, and Amy Lovett-Racke. "Identifying the cytokines provided by antigen-presenting cells critical for generating an encephalitogenic T cell (BA11P.126)." Journal of Immunology 194, no. 1_Supplement (2015): 184.8. http://dx.doi.org/10.4049/jimmunol.194.supp.184.8.
Pełny tekst źródła